Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.

Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solórzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, García-Sastre A, Palese P, Krammer F.

Lancet Infect Dis. 2019 Oct 17. pii: S1473-3099(19)30393-7. doi: 10.1016/S1473-3099(19)30393-7. [Epub ahead of print]

2.

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.

Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.

Pediatr Infect Dis J. 2019 Jun;38(6):643-650. doi: 10.1097/INF.0000000000002334.

PMID:
31116180
3.

Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R.

Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022.

4.

Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.

Rivera L, Schwarz TF, Kim KH, Kim YK, Behre U, Cha SH, Jo DS, Lee J, Lee JS, Cheuvart B, Jastorff A, Van der Wielen M.

Vaccine. 2018 Jul 25;36(31):4750-4758. doi: 10.1016/j.vaccine.2018.04.034. Epub 2018 Jun 28.

5.

MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.

Rivera L, Chanthavanich P, Põder A, Suryakiran PV, Jastorff A, Van der Wielen M.

Vaccine. 2018 Jun 22;36(27):3967-3975. doi: 10.1016/j.vaccine.2018.05.051. Epub 2018 May 19.

6.

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.

Dbaibo G, Tinoco Favila JC, Traskine M, Jastorff A, Van der Wielen M.

Vaccine. 2018 Jun 27;36(28):4102-4111. doi: 10.1016/j.vaccine.2018.05.046. Epub 2018 May 18.

7.

Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.

Knuf M, Helm K, Kolhe D, Van Der Wielen M, Baine Y.

Vaccine. 2018 May 31;36(23):3286-3295. doi: 10.1016/j.vaccine.2018.04.064. Epub 2018 Apr 30.

8.

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.

Merino Arribas JM, Carmona Martínez A, Horn M, Perez Porcuna XM, Otero Reigada MDC, Marès Bermúdez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, Christoph W, Bleckmann G, Fischbach T, Kolhe D, Van der Wielen M, Baine Y.

Pediatr Infect Dis J. 2018 Jul;37(7):704-714. doi: 10.1097/INF.0000000000002061.

PMID:
29620722
9.

Comparison of Outcomes and Intervention Among Patients With Non-ST-Segment Elevation Acute Myocardial Infarction of Those With a Left Circumflex Versus Those With a Non-Left Circumflex-Related Coronary Artery (From the ELISA-3 Trial).

Badings EA, Hermanides RS, The SHK, Dambrink JE, Rasoul S, Van Wijngaarden J, Van 't Riet E, Kolkman E, Remkes WS, Tjeerdsma G, Van Der Wielen MLJ, Lok DJA, Suryapranata H, Van 't Hof AWJ.

Am J Cardiol. 2018 May 15;121(10):1123-1128. doi: 10.1016/j.amjcard.2018.01.031. Epub 2018 Feb 21.

PMID:
29606324
10.

Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.

Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.

Vaccine. 2018 Apr 19;36(17):2356-2363. doi: 10.1016/j.vaccine.2018.02.085. Epub 2018 Mar 22.

11.

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.

Cutland CL, Nolan T, Halperin SA, Kurugol Z, Ahmed K, Perrett KP, Richmond P, Marshall HS, Ceyhan M, Kolhe D, Hezareh M, Van Der Wielen M.

Vaccine. 2018 Mar 27;36(14):1908-1916. doi: 10.1016/j.vaccine.2018.02.013. Epub 2018 Mar 2.

12.

Two-year outcome after early or late Intervention in non-ST elevation acute coronary syndrome.

Badings EA, Remkes WS, The SH, Dambrink JE, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, Hermanides RS, Van Wijngaarden J, Suryapranata H, van 't Hof AW.

Open Heart. 2017 Mar 2;4(1):e000538. doi: 10.1136/openhrt-2016-000538. eCollection 2017.

13.

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.

Quiambao BP, Bavdekar A, Dubey AP, Jain H, Kolhe D, Bianco V, Miller JM, Van der Wielen M.

Hum Vaccin Immunother. 2017 Mar 4;13(3):636-644. doi: 10.1080/21645515.2016.1248009. Epub 2017 Feb 2.

14.

Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.

Merino Arribas JM, Carmona Martínez A, Horn M, Perez Porcuna XM, Otero Reigada MD, Marès Bermúdez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, Wittermann C, Bleckmann G, Fischbach T, Kolhe D, van der Wielen M, Baine Y.

Pediatr Infect Dis J. 2017 Apr;36(4):e98-e107. doi: 10.1097/INF.0000000000001484.

PMID:
28002359
15.

Early or late intervention in patients with transient ST-segment elevation acute coronary syndrome: Subgroup analysis of the ELISA-3 trial.

Badings EA, Remkes WS, The SH, Dambrink JE, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, Hermanides R, van Wijngaarden J, Suryapranata H, van 't Hof AW.

Catheter Cardiovasc Interv. 2016 Nov;88(5):755-764. doi: 10.1002/ccd.26719. Epub 2016 Aug 27.

PMID:
27567144
16.

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.

Quiambao BP, Jain H, Bavdekar A, Dubey AP, Kolhe D, Bianco V, Van der Wielen M, Miller JM.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2162-2168. Epub 2016 May 6.

17.
18.

Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.

Klein NP, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.

Pediatr Infect Dis J. 2016 Jun;35(6):662-72. doi: 10.1097/INF.0000000000001123.

PMID:
26928521
19.

Timing of intervention in high-risk non-ST-elevation acute coronary syndromes in PCI versus non-PCI centres : Sub-group analysis of the ELISA-3 trial.

Badings EA, Remkes WS, Dambrink JH, The SH, Van Wijngaarden J, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, van 't Hof AW.

Neth Heart J. 2016 Mar;24(3):181-7. doi: 10.1007/s12471-015-0801-7.

21.

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.

Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.

Hum Vaccin Immunother. 2016;12(1):132-9. doi: 10.1080/21645515.2015.1058457.

22.

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.

Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.

BMC Infect Dis. 2015 Oct 6;15:409. doi: 10.1186/s12879-015-1138-y.

23.

Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.

Booy R, Nolan T, Reynolds G, Richmond P, Nissen M, Marshall H, Stoney T, Van Der Wielen M, Kolhe D, Miller JM.

Pediatr Infect Dis J. 2015 Dec;34(12):1379-84. doi: 10.1097/INF.0000000000000898.

PMID:
26372451
24.

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.

Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.

Pediatr Infect Dis J. 2015 Nov;34(11):1236-43. doi: 10.1097/INF.0000000000000866.

PMID:
26237742
25.

A novel variant of FGFR3 causes proportionate short stature.

Kant SG, Cervenkova I, Balek L, Trantirek L, Santen GW, de Vries MC, van Duyvenvoorde HA, van der Wielen MJ, Verkerk AJ, Uitterlinden AG, Hannema SE, Wit JM, Oostdijk W, Krejci P, Losekoot M.

Eur J Endocrinol. 2015 Jun;172(6):763-70. doi: 10.1530/EJE-14-0945. Epub 2015 Mar 16.

PMID:
25777271
26.

Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients.

Santen GW, Aten E, Vulto-van Silfhout AT, Pottinger C, van Bon BW, van Minderhout IJ, Snowdowne R, van der Lans CA, Boogaard M, Linssen MM, Vijfhuizen L, van der Wielen MJ, Vollebregt MJ; Coffin-Siris consortium, Breuning MH, Kriek M, van Haeringen A, den Dunnen JT, Hoischen A, Clayton-Smith J, de Vries BB, Hennekam RC, van Belzen MJ.

Hum Mutat. 2013 Nov;34(11):1519-28. doi: 10.1002/humu.22394. Epub 2013 Aug 30.

PMID:
23929686
27.

Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.

Lupisan S, Limkittikul K, Sosa N, Chanthavanich P, Bianco V, Baine Y, Van der Wielen M, Miller JM.

Clin Vaccine Immunol. 2013 Oct;20(10):1499-507. doi: 10.1128/CVI.00162-13. Epub 2013 Jul 24.

28.

Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial.

Badings EA, The SH, Dambrink JH, van Wijngaarden J, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, van 't Hof AW.

EuroIntervention. 2013 May 20;9(1):54-61. doi: 10.4244/EIJV9I1A9.

29.
30.

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).

Østergaard L, Van der Wielen M, Bianco V, Miller JM.

Int J Infect Dis. 2013 Mar;17(3):e173-6. doi: 10.1016/j.ijid.2012.10.001. Epub 2012 Dec 13.

31.

Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.

Ruiz-Palacios GM, Huang LM, Lin TY, Hernandez L, Guerrero ML, Villalobos AL, Van der Wielen M, Moreira M, Fissette L, Borys D, Miller JM.

Pediatr Infect Dis J. 2013 Jan;32(1):62-71. doi: 10.1097/INF.0b013e3182784143.

PMID:
23076383
32.

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.

Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1882-91. doi: 10.4161/hv.22165. Epub 2012 Oct 2.

33.

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1892-903. doi: 10.4161/hv.22166. Epub 2012 Oct 2.

34.

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.

Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM.

Int J Infect Dis. 2012 Aug;16(8):e608-15. doi: 10.1016/j.ijid.2012.04.006. Epub 2012 Jun 14.

35.

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience.

Miller JM, Mesaros N, Van Der Wielen M, Baine Y.

Adv Prev Med. 2011;2011:846756. doi: 10.4061/2011/846756. Epub 2011 Jul 18.

36.
37.

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.

Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, Bianco V, Van der Wielen M, Miller JM.

Vaccine. 2011 Jun 6;29(25):4264-73. doi: 10.1016/j.vaccine.2011.03.009. Epub 2011 Mar 21.

PMID:
21420417
38.

Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age.

van Damme P, Kafeja F, Van Der Wielen M, Leyssen M, Jacquet JM.

Pediatr Infect Dis J. 2011 Aug;30(8):703-5. doi: 10.1097/INF.0b013e3182138296.

PMID:
21346683
39.

Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.

Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, Bianco V, Van der Wielen M, Gatchalian S, Miller JM.

Pediatr Infect Dis J. 2011 Apr;30(4):e56-62. doi: 10.1097/INF.0b013e31820e6e02.

PMID:
21278617
40.

Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2.

Aten E, Brasz LC, Bornholdt D, Hooijkaas IB, Porteous ME, Sybert VP, Vermeer MH, Vossen RH, van der Wielen MJ, Bakker E, Breuning MH, Grzeschik KH, Oosterwijk JC, den Dunnen JT.

Hum Mutat. 2010 Oct;31(10):1125-33. doi: 10.1002/humu.21335.

PMID:
20672378
41.

Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study.

Van der Wielen M, Giaquinto C, Gothefors L, Huelsse C, Huet F, Littmann M, Maxwell M, Talayero JM, Todd P, Vila MT, Cantarutti L, Van Damme P; REVEAL Study Group.

BMC Fam Pract. 2010 Mar 15;11:22. doi: 10.1186/1471-2296-11-22.

42.

Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.

Leroux-Roels I, Van der Wielen M, Kafeja F, Vandermeulen C, Lazarus R, Snape MD, John T, Carre C, Nougarede N, Pepin S, Leroux-Roels G, Hoppenbrouwers K, Pollard AJ, Van Damme P.

Vaccine. 2009 Nov 16;27(49):6918-25. doi: 10.1016/j.vaccine.2009.08.110. Epub 2009 Sep 15.

PMID:
19761837
43.

The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients.

Bayley JP, Grimbergen AE, van Bunderen PA, van der Wielen M, Kunst HP, Lenders JW, Jansen JC, Dullaart RP, Devilee P, Corssmit EP, Vriends AH, Losekoot M, Weiss MM.

BMC Med Genet. 2009 Apr 15;10:34. doi: 10.1186/1471-2350-10-34.

44.

RNF135 mutations are not present in patients with Sotos syndrome-like features.

Visser R, Koelma N, Vijfhuizen L, van der Wielen MJ, Kant SG, Breuning MH, Wit JM, Losekoot M.

Am J Med Genet A. 2009 Feb 15;149A(4):806-8. doi: 10.1002/ajmg.a.32694. No abstract available.

PMID:
19291764
45.

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.

Vaccine. 2009 Jan 14;27(3):454-9. doi: 10.1016/j.vaccine.2008.10.077. Epub 2008 Nov 18.

PMID:
19022318
46.

Search for copy number alterations in the MEFV gene using multiplex ligation probe amplification, experience from three diagnostic centres.

van Gijn ME, Soler S, de la Chapelle C, Mulder M, Ritorre C, Kriek M, Philibert L, van der Wielen M, Frenkel J, Grandemange S, Bakker E, Ploos van Amstel JK, Touitou I.

Eur J Hum Genet. 2008 Nov;16(11):1404-6. doi: 10.1038/ejhg.2008.135. Epub 2008 Jul 23.

47.

Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial.

Van der Wielen M, Van Damme P.

Eur J Clin Microbiol Infect Dis. 2008 Jul;27(7):495-501. doi: 10.1007/s10096-008-0479-5. Epub 2008 Mar 20. Review.

PMID:
18351405
48.

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine.

Stojanov S, Liese JG, Belohradsky BH, Vandermeulen C, Hoppenbrouwers K, Van der Wielen M, Van Damme P, Georges B, Dupuy M, Scemama M, Watson M, Fiquet A, Stek JE, Golm GT, Schödel FP, Kuter BJ; HEXAVAC/VAQTA Study Group.

Vaccine. 2007 Oct 23;25(43):7549-58. Epub 2007 Sep 4.

PMID:
17905486
49.

Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.

Van Der Wielen M, Vertruyen A, Froesner G, Ibáñez R, Hunt M, Herzog C, Van Damme P.

Pediatr Infect Dis J. 2007 Aug;26(8):705-10.

PMID:
17848882
50.

Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study.

Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M; REVEAL Study Group.

J Infect Dis. 2007 May 1;195 Suppl 1:S36-S44.

PMID:
17539193

Supplemental Content

Loading ...
Support Center